Next-Generation Small Molecule Checkpoint Inhibitor Targeting Castration-Resistant Prostate Cancer BRANFORD, CT., April 3, 2017 – BioXcel, a biopharmaceutical company integrating big data analytics and machine learning-based artificial intelligence (AI) with drug development expertise to advance the next wave of medicines, Read More